To the Editor In a Viewpoint on cholesterol treatment in 2017, Dr Krumholz argued that prescribing statins for secondary prevention of vascular disease or in individuals at higher disease risk is supported by estimates from clinical trials that the number of preventable vascular events over 5 years far exceeds that of anticipated adverse events.1 He later asserted, without evidence, that “For lower-risk individuals, treatment with statins provides a smaller benefit, but many will find the benefits to outweigh risks.”
Regenold WT. Risks of Statins for Lower-Risk Individuals. JAMA. 2018;319(3):309–310. doi:10.1001/jama.2017.19170
Customize your JAMA Network experience by selecting one or more topics from the list below.